FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b									
hours per response:	nuidell 0 E								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Barnett Valerie (Last) (First) (Middle) C/O CYTEK BIOSCIENCES, INC. 47215 LAKEVIEW BOULEVARD (Street) FREMONT CA 94538					Issuer Name and Ticker or Trading Symbol Cytek Biosciences, Inc. [CTKB] Inc. [CTKB]							6. li	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(City)	(S		(Zip)											_				
1. Title of Security (Instr. 3) 2. Trans Date (Months				2. Transa Date Month/D	2A. Deemed Execution Date, if any (Month/Day/Yea		3. Trans Code 8)	saction (Instr	r. 5)		ed (A) or tr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	te, 4.	ansactio	5. on of tr. De Se Ac (A Di of	. Number 6.		, options, co 6. Date Exercisa Expiration Date (Month/Day/Yea		sable and	7. Title and of Securit Underlyin Derivative (Instr. 3 and	d Amount ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	ode V	(A	A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$10.61	03/03/2023			A	89	9,031		(1)		03/03/2033	Common Stock	89,031	\$0.00	89,031		D	
Restricted Stock Units	(2)	03/03/2023			A	58	8,906		(3)		(3)	Common Stock	58,906	\$0.00	58,906	5	D	

Explanation of Responses:

- 1. 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027.
- 2. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- 3. The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.

Remarks:

/s/ Valerie Barnett

03/07/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.